|
|
|
|
06.05.25 - 08:39
|
Hims & Hers mit Top-Zahlen nach Novo-Nordisk-Deal – Aktie fällt (Der Aktionaer)
|
|
Am Montag nach US-Börsenschluss hat das US-Unternehmen Hims & Hers die Zahlen für das erste Quartal vorgelegt und durch die Bank überzeugt. Dennoch verliert die Aktie im nachbörslichen Handel wieder an Boden. Im Vorfeld war das Papier durch das Bekanntwerden einer Zusammenarbeit mit Novo Nordisk bereits kräftig angesprungen....
|
|
06.05.25 - 00:36
|
Hims & Hers (HIMS) Blows Out Earnings Expectations (24/7 Wall St.)
|
|
Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, marking a 111% increase year-over-year. The company achieved a net income of $49.5 million, significantly up from $26.0 million in the previous quarter, and an Adjusted EBITDA of $91.1 million. Subscriber growth was robust, with a 38% […]
The post Hims & Hers (HIMS) Blows Out Earnings Expectations appeared first on 24/7 Wall St.....
|
|
|
|
|
05.05.25 - 16:48
|
Hims & Hers (NYSE: HIMS) Live: Complete Earnings Coverage (24/7 Wall St.)
|
|
Live Updates Live Coverage Updates appear automatically as they are published. Watching for GLP-1 Fallout 10:14 am by Joel South The telehealth platform was hit earlier this year by the Food & Drug Administration declaring there was no longer a shortage of Ozempic or Wegovy, the GLP-1 drugs sold by Novo Nordisk (NYSE:NVO) for the […]
The post Hims & Hers (NYSE: HIMS) Live: Complete Earnings Coverage appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
|
|
|
|